Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

249.29
-10.9400-4.20%
Post-market: 248.16-1.1299-0.45%18:35 EDT
Volume:2.37M
Turnover:602.62M
Market Cap:16.18B
PE:17.04
High:259.83
Open:257.40
Low:248.52
Close:260.23
52wk High:266.38
52wk Low:122.50
Shares:64.91M
Float Shares:62.69M
Volume Ratio:3.40
T/O Rate:3.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.37
PE(LYR):-42.68

Loading ...

FDA Approves Test to Identify Gastroesophageal Cancer Patients Eligible for Jazz Pharmaceuticals' Ziihera

MT Newswires Live
·
3 hours ago

Jazz Pharmaceuticals is Maintained at Overweight by Morgan Stanley

Dow Jones
·
6 hours ago

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Yesterday

Jazz Pharmaceuticals price target raised to $281 from $264 at Truist

TIPRANKS
·
Yesterday

Jazz Pharmaceuticals Plans $1 Billion Exchangeable Senior Notes Due 2032

MT Newswires Live
·
Yesterday

Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes Due 2032 and Concurrent Ordinary Share Repurchases

THOMSON REUTERS
·
Yesterday

Jazz Pharmaceuticals - Initial Purchasers May Buy up to $150 Mln Additional Notes

THOMSON REUTERS
·
Yesterday

Jazz Pharmaceuticals - Expects to Repurchase up to $225 Mln of Ordinary Shares Concurrently

THOMSON REUTERS
·
Yesterday

Jazz Pharmaceuticals - Net Proceeds from Offering Expected to be Used for General Corporate Purposes

THOMSON REUTERS
·
Yesterday

Piper Sandler Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Yesterday

RBC Adjusts Price Target on Jazz Pharmaceuticals Public to $277 From $273, Maintains Outperform Rating

MT Newswires Live
·
Yesterday

Jazz Pharmaceuticals Highlights Ziihera Launch, Targets $3-$5 Billion Zanidatamab Peak Sales Opportunity

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX)

TIPRANKS
·
Yesterday

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Yesterday

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $281 from $264

THOMSON REUTERS
·
Yesterday

Jazz Pharma Says FDA Approves Ziihera Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma

Reuters
·
Aug 25

Jazz Pharmaceuticals - Ziihera U.S. Prescribing Information Includes Boxed Warnings for Diarrhea and Embryo-Fetal Toxicity

THOMSON REUTERS
·
Aug 25

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) with and Without Tislelizumab Plus Chemotherapy in First-Line Her2+ Advanced Gastroesophageal Adenocarcinoma

THOMSON REUTERS
·
Aug 25

Funds: What a Top Biotech Fund is Buying Now

Dow Jones
·
Aug 22

Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative

Simply Wall St.
·
Aug 21